Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 5/20 | 0.47 |
| ▸ | CHUK | O15111 | 3/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814584 | 0.84 | IKBKB (0.52) | IKBKBCHUKTLR7KMT2AMEN1 | |
| SCHEMBL2814034 | 0.82 | TLR7 (0.44) | TLR7SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL2815048 | 0.82 | TLR7 (0.56) | TLR7SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL2815787 | 0.81 | HTR2C (0.50) | HTR2CIKBKBCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL12440249 | 0.80 | HTR2C (0.49) | HTR2CIKBKBCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL2816324 | 0.80 | TLR7 (0.43) | TLR7SMN1; SMN2LMNAHIF1AKMT2A | |
| SCHEMBL2816012 | 0.80 | TLR7 (0.43) | IKBKBTLR7SMN1; SMN2LMNAKMT2A | |
| SCHEMBL2819718 | 0.77 | IKBKB (0.69) | HTR2CIKBKBCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL2816677 | 0.75 | HTR2C (0.51) | HTR2CIKBKBCHUKTOP2ASMN1; SMN2 | |
| SCHEMBL2820509 | 0.73 | TOP2A (0.52) | HTR2CTOP2ATLR7SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | HTR2C 1292/4885IKBKB 855/4885CHUK 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.